Conmed Corporation Stock Downgraded (CNMD)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Conmed Corporation (Nasdaq: CNMD) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • CNMD's revenue growth has slightly outpaced the industry average of 2.6%. Since the same quarter one year prior, revenues slightly increased by 5.2%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • Although CNMD's debt-to-equity ratio of 0.28 is very low, it is currently higher than that of the industry average. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.23, which illustrates the ability to avoid short-term cash problems.
  • CONMED CORP has improved earnings per share by 10.3% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, CONMED CORP reported lower earnings of $0.00 versus $1.05 in the prior year. This year, the market expects an increase in earnings to $1.79 from $0.00.
  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, CONMED CORP's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has decreased to $27.99 million or 23.29% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
.

CONMED Corporation, a medical technology company, provides surgical devices and equipment for minimally invasive procedures and monitoring. The company has a P/E ratio of 165.9, above the S&P 500 P/E ratio of 17.7. Conmed has a market cap of $756 million and is part of the health care sector and health services industry. Shares are up 3.4% year to date as of the close of trading on Monday.

You can view the full Conmed Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

Voce's Plants Eyes Stockholder Value, Director Battle at Air Methods

Voce's Plants Eyes Stockholder Value, Director Battle at Air Methods

Insider Trading Alert - CNMD, GLAD And IPHI Traded By Insiders

Insider Trading Alert - CNMD, GLAD And IPHI Traded By Insiders

Daniel Plants' Voce Fund Returns 5% as Other Activist Investors Struggle

Daniel Plants' Voce Fund Returns 5% as Other Activist Investors Struggle

Insider Trading Alert - CNMD, AL And CNBKA Traded By Insiders

Insider Trading Alert - CNMD, AL And CNBKA Traded By Insiders

6 Medical Device Stocks to Buy If Ted Cruz Is Elected President

6 Medical Device Stocks to Buy If Ted Cruz Is Elected President